What question did this study set out to answer?

The study aims to assess the changes in treatment and outcomes for patients undergoing radical cystectomy over two decades.

June 3, 2026BMC Urology0 citationsOpen Access

Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center

CSCaio Vinícius Suartz MAMaria Fernanda Dias Azevedo PBPedro Henrique Souza Brito

Key Points

The study aims to assess the changes in treatment and outcomes for patients undergoing radical cystectomy over two decades.
Retrospective analysis of clinical, surgical, and pathological data from 733 patients who underwent radical cystectomy.
Patients were divided into cohorts based on the year of surgery (2005–2014 vs. 2015–2025).
Survival analyses utilized Kaplan–Meier curves to compare overall survival, cancer-specific survival, and recurrence-free survival.
Treatment period was associated with improved overall survival (HR 0.75, 95% CI 0.58–0.97; p = 0.029).
Patients from 2015–2025 showed significantly better overall, cancer-specific, and recurrence-free survival than those from 2005–2014 (all log-rank p < 0.001).
Advanced clinical stage increased the hazard of death (HR 1.48, 95% CI 1.08–2.02; p = 0.015).

Abstract

Over the last two decades, significant advances in the perioperative management of muscle-invasive bladder cancer, such as enhanced recovery protocols, increased use of neoadjuvant chemotherapy, improved care pathways, and stronger multidisciplinary collaboration, have reshaped surgical outcomes. This study aimed to evaluate the evolution of care and oncological outcomes in patients undergoing radical cystectomy at a Brazilian tertiary cancer center over 20 years. We retrospectively analyzed clinical, surgical, and pathological data from patients with bladder cancer who underwent radical cystectomy between January 2005 and April 2025. Patients were stratified into two cohorts according to the year of surgery (2005–2014 vs. 2015–2025). Survival analyses were performed using Kaplan–Meier curves to compare overall survival, cancer-specific survival, and recurrence-free survival between periods. A total of 733 patients were included (mean age, 66.2 years; 69.2% male). An age-adjusted Charlson Comorbidity Index ≥ 3 was present in 90.4%, and preoperative hydronephrosis in 41.5%. Locally advanced disease (pT3–pT4) occurred in 50.9%, lymph node positivity (pN+) in 26.6%, and 34.5% received neoadjuvant chemotherapy. Early complications (< 30 days) occurred in 51.2%, early reoperation in 19.3%, and late complications (30–90 days) in 24.0%, with 33.3% classified as Clavien–Dindo grade ≥ III. On multivariable Cox regression, treatment period remained independently associated with improved overall survival (HR 0.75, 95% CI 0.58–0.97; p = 0.029). Clinical stage was also independently associated with overall survival (overall p = 0.046), with advanced stage increasing the hazard of death (HR 1.48, 95% CI 1.08–2.02; p = 0.015). Kaplan–Meier analysis showed significantly improved overall, cancer-specific, and recurrence-free survival in 2015–2025 versus 2005–2014 (all log-rank p < 0.001). Improved survival after radical cystectomy over the last decade reflects advances in perioperative care in the management of bladder cancer patients undergoing radical cystectomy.

问 AI

Bookmark

View Full Paper